Cargando…

Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer

Dasatinib is a multi-target kinase inhibitor, whose targets include BCR-ABL, SRC family kinases, and various cancer kinases. The elevated SRC activity in gastric cancer (GC) has prompted the need for the therapeutic application of dasatinib in GC. We observed that the efficacy of dasatinib varied wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Kyoung-Min, Cho, Eunji, Bang, Geul, Lee, Seong-Jae, Kim, Boram, Kim, Ji-Hee, Park, Seo-Gyu, Han, Eun Hee, Chung, Young-Ho, Kim, Jin Young, Kim, Eunjung, Kim, Jae-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729964/
https://www.ncbi.nlm.nih.gov/pubmed/33291786
http://dx.doi.org/10.3390/ijms21239276
_version_ 1783621578195468288
author Choi, Kyoung-Min
Cho, Eunji
Bang, Geul
Lee, Seong-Jae
Kim, Boram
Kim, Ji-Hee
Park, Seo-Gyu
Han, Eun Hee
Chung, Young-Ho
Kim, Jin Young
Kim, Eunjung
Kim, Jae-Young
author_facet Choi, Kyoung-Min
Cho, Eunji
Bang, Geul
Lee, Seong-Jae
Kim, Boram
Kim, Ji-Hee
Park, Seo-Gyu
Han, Eun Hee
Chung, Young-Ho
Kim, Jin Young
Kim, Eunjung
Kim, Jae-Young
author_sort Choi, Kyoung-Min
collection PubMed
description Dasatinib is a multi-target kinase inhibitor, whose targets include BCR-ABL, SRC family kinases, and various cancer kinases. The elevated SRC activity in gastric cancer (GC) has prompted the need for the therapeutic application of dasatinib in GC. We observed that the efficacy of dasatinib varied with the GC cell lines. The differential effect of dasatinib was not correlated with the basal SRC activity of each cell line. Moreover, the GC cell lines showing the strong antitumor effects of dasatinib were refractory to other SRC inhibitors, i.e., bosutinib and saracatinib, suggesting that unexpected dasatinib’s targets could exist. To profile the targets of dasatinib in GC, we performed activity-based protein profiling (ABPP) via mass spectrometry using a desthiobiotin-ATP probe. We identified 29 and 18 kinases as potential targets in dasatinib-sensitive (SNU-216, MKN-1) and -resistant (SNU-484, SNU-601) cell lines, respectively. The protein–protein interaction mapping of the differential drug targets in dasatinib-sensitive and -resistant GC using the STRING database suggested that dasatinib could target cellular energy homeostasis in the drug-sensitive GC. RNAi screening for identified targets indicated p90RSK could be a novel dasatinib target, which is important for maintaining the viability and motility of GC cells. Further functional validation of dasatinib off-target actions will provide more effective therapeutic options for GC.
format Online
Article
Text
id pubmed-7729964
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77299642020-12-12 Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer Choi, Kyoung-Min Cho, Eunji Bang, Geul Lee, Seong-Jae Kim, Boram Kim, Ji-Hee Park, Seo-Gyu Han, Eun Hee Chung, Young-Ho Kim, Jin Young Kim, Eunjung Kim, Jae-Young Int J Mol Sci Article Dasatinib is a multi-target kinase inhibitor, whose targets include BCR-ABL, SRC family kinases, and various cancer kinases. The elevated SRC activity in gastric cancer (GC) has prompted the need for the therapeutic application of dasatinib in GC. We observed that the efficacy of dasatinib varied with the GC cell lines. The differential effect of dasatinib was not correlated with the basal SRC activity of each cell line. Moreover, the GC cell lines showing the strong antitumor effects of dasatinib were refractory to other SRC inhibitors, i.e., bosutinib and saracatinib, suggesting that unexpected dasatinib’s targets could exist. To profile the targets of dasatinib in GC, we performed activity-based protein profiling (ABPP) via mass spectrometry using a desthiobiotin-ATP probe. We identified 29 and 18 kinases as potential targets in dasatinib-sensitive (SNU-216, MKN-1) and -resistant (SNU-484, SNU-601) cell lines, respectively. The protein–protein interaction mapping of the differential drug targets in dasatinib-sensitive and -resistant GC using the STRING database suggested that dasatinib could target cellular energy homeostasis in the drug-sensitive GC. RNAi screening for identified targets indicated p90RSK could be a novel dasatinib target, which is important for maintaining the viability and motility of GC cells. Further functional validation of dasatinib off-target actions will provide more effective therapeutic options for GC. MDPI 2020-12-04 /pmc/articles/PMC7729964/ /pubmed/33291786 http://dx.doi.org/10.3390/ijms21239276 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Kyoung-Min
Cho, Eunji
Bang, Geul
Lee, Seong-Jae
Kim, Boram
Kim, Ji-Hee
Park, Seo-Gyu
Han, Eun Hee
Chung, Young-Ho
Kim, Jin Young
Kim, Eunjung
Kim, Jae-Young
Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title_full Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title_fullStr Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title_full_unstemmed Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title_short Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
title_sort activity-based protein profiling reveals potential dasatinib targets in gastric cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729964/
https://www.ncbi.nlm.nih.gov/pubmed/33291786
http://dx.doi.org/10.3390/ijms21239276
work_keys_str_mv AT choikyoungmin activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT choeunji activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT banggeul activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT leeseongjae activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT kimboram activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT kimjihee activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT parkseogyu activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT haneunhee activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT chungyoungho activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT kimjinyoung activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT kimeunjung activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer
AT kimjaeyoung activitybasedproteinprofilingrevealspotentialdasatinibtargetsingastriccancer